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Summary
Although cystic fibrosis patients display multi organ dysfunction (e.g. pancreas, gut, lung) it is lung
disease that is the leading cause of premature death in these patients. Cystic fibrosis lung disease is
characterized by persistent pulmonary infection and mucus plugging of the airways initiated by
failure of solute transport across the airway epithelium. Many drug therapies aim to alleviate the
secondary characteristics of CF lung disease, however, new therapies in development are targeted at
correcting the ion transport deficiency of CF. The goal is to hydrate airway surfaces by stimulating
secretion (through activation of the cystic fibrosis transmembrane conductance regulator and calcium
activated chloride channels), and/or inhibiting absorption (through the epithelial sodium channel)
thereby stimulating healthy mucociliary clearance. If mucociliary clearance can be stimulated
sufficiently from an early age then there is the possibility that secondary lung infection may be
eradicated from the syndrome of CF disease.
Introduction
Currently, the drug development pipeline described by the North American Cystic Fibrosis
Foundation lists 33 drugs that are developed or in development for the treatment of cystic
fibrosis (CF, http://www.cff.org/research/DrugDevelopmentPipeline). Of these drugs, many
target the infection and inflammation present in the CF lung, the aim being to ameliorate
symptoms and recover lung function rather than correct the basic CF defect. However, a third
of the drugs listed in the pipeline focus on correction of the ion transport deficiency of CF, and
have the potential to delay or arrest the development of CF lung disease (see Table 1).
In the simplest pathophysiological scenario, the absence of functional CFTR (cystic fibrosis
transmembrane conductance regulator) at the apical membrane of ciliated airway epithelial
cells, results in 1) a reduced capacity to secrete Cl− and water to the airway surface and 2) a
failure to regulate absorption of Na+ and water from airway surfaces [1,2]. This imbalance of
active ion transport favors the net removal of salt and water from airway surfaces. Loss of
water in the periciliary gel layer (PCL) results in a loss of lubrication of the airway surface and
increased concentrations of mucin (the secreted glycoproteins) in the mucus layer (mix of
glycoproteins, DNA, proteins, water, electrolytes and other components). Dehydrated PCL
leads to collapse of cilia, thickening of the mucus layer and the creation of an adhesive mass
that ultimately produces mucus plugging and mucus plaques on airway surfaces [3–6] (see
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Figure 1). These plaques serve as the nidus for the persistent bacterial infection that
characterizes CF, stimulate inflammation, obstruct the airway lumen, and produce the airflow
obstruction characteristic of CF patients [7,8]. Thus, pharmacotherapies directed at treating the
proximate cause of CF lung disease have recently focused on restoring the hydration of the
airway surface and, hence, restoring mucus clearance.
POTENTIAL THERAPEUTIC AGENTS – REHYDRATING AGENTS
A. Osmotic agents
Hypertonic saline (HS)—Inhaled HS acts as an osmotic agent to draw water onto airway
surfaces (see Figure 2). Ironically, HS is more active when deposited on CF airway epithelia
than on normal airway epithelia. The NaCl concentration gradient formed by aerosol deposition
within ASL is dissipated more slowly across a CF airway epithelium. This is because CF
airways only have active Na+ channels, compared to normal airway epithelia that express active
Na+ and Cl− channels [9]. For this reason, NaCl remains on CF airway surfaces for longer
periods of time and is more osmotically active, drawing more water to airway surfaces.
A number of short-term studies (< 2 weeks, or single doses) performed in the mid-1990’s
through 2000 measured the immediate effects of aerosolized HS on mucociliary clearance and
lung function [10–13]. These studies reported that HS restored defective mucociliary clearance
in CF patients, but was accompanied by short term fall in FEV1 (<5%). Subsequently, in 2006,
two papers appeared that strongly supported the hydration mechanism of action of HS and its
longer term efficacy in CF. In the first, Donaldson et al. showed that HS alone increased basal
mucociliary transport over a two-week interval (7% HS, q.i.d., by PariLCStar) and increased
both FEV1 and FEF25–75% [14]**. Interestingly, pretreatment with amiloride, designed to slow
the absorption of Na+ from airway surfaces and hence potentiate the hydrating effects of HS,
actually blunted the response of CF patients with respect to both mucus clearance and lung
function. Subsequent studies suggested that amiloride blocked an apical membrane aquaporin
in human airway epithelial cells; likely aquaporin 5, suggesting that indeed, osmotically driven
water flow to the surface was the therapeutic mechanism of action for hypertonic saline [15].
In a companion paper to [14], Elkins et al. showed that inhalation of HS (7%, b.i.d., PariLCStar)
was associated with a modest but sustained increase in lung function and a dramatic 40–60%
reduction in acute infectious exacerbations [16]**. Prolonged HS therapy appeared to be safe
and was actually associated with fewer acquisitions of new organisms than vehicle.
HS studies are now being extended in several directions. First, there are studies ongoing
designed to deliver HS aerosols to adolescent/adult subjects by more rapid delivery devices,
e.g., by the Pari-eFlow. Second, and perhaps most importantly, the potential efficacy of HS in
preventing lung disease in infants is being tested. Preliminary short-term studies of HS
inhalation in CF infants have shown that this therapy appears to be safe, based on imaging and
pulmonary function tests. It is anticipated that a large multi-Center study to test whether HS
can prevent CF lung disease/exacerbations will be initiated (3%, Pari Sprint nebulizer, b.i.d.)
in CF infants nationwide (USA) by the summer of 2008. Currently, it is estimated that more
than 25% of CF patients in the U.S. are using HS therapy.
Bronchitol (inhaled mannitol)—Inhaled mannitol, like hypertonic saline, acts as an
osmotic agent. Its higher molecular weight ensures that mannitol gradients in the ASL dissipate
slowly via permeation through the pericellular path. Thus, mannitol may have a longer osmotic
effect on airway surfaces than HS. However, this advantage is, to some degree, offset by the
greater molecular weight of mannitol (~180 MW per one osmole) versus NaCl (53 MW per 2
osmoles). Thus, a large mass of mannitol must be inhaled to produce a significant osmotic
driving force. Currently, dry mannitol powder is being administered via a unique dry powder
device. To achieve a 420 mg inhaled therapeutic dose, the contents of ~14 capsules (30 mg)
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must be inhaled per dosing session (i.e. > b.i.d). Results from Phase I studies suggested that
inhaled mannitol is relatively well-tolerated, particularly if pretreatment with a bronchodilator
is performed [12]. Results from a one-month Phase II study showed substantial improvement
of FEV1 and FEF25–75%, at values comparable to those observed by Donaldson et al. [14] with
hypertonic saline, in CF subjects [17]**. Currently, a large (~360 subject) three-month CF
Phase III trial has been fully enrolled in the U.K., Australia, and New Zealand, and there are
plans to initiate Phase III studies in the U.S.
B. Alternative Cl− channel activators
Denufosol (INS37217)—Aerosolized Denufosol is a UTP analog that was designed to resist
metabolism by cell surface ecto-ATPases, and, have greater efficacy by increasing its residence
time on airway surfaces. The concept is that INS37217 will chronically activate P2Y2 receptors,
leading to a persistent increase in Ca2+-activated Cl− channel (CaCC) activity in CF patients
and a modest inhibition of the epithelial Na+ channel (ENaC). Phase I studies revealed that the
compound was safe and well-tolerated by normal and CF subjects [18]. Phase II studies
revealed that inhalation of INS37217 over one-month (t.i.d) prevented the typical CF lung
disease-induced loss of lung function with time [19]. This effect was most pronounced in
patients who had an FEV1 of > 75% predicted, and no strict dose dependence was observed in
doses of 20, 40, and 60 mg (dosed via PariLCStar nebulizer). Interestingly, positive interactions
were observed between the use of an enzyme that cleaves DNA, DNAse (Pulmonzyme), and
INS37217. Currently, the first of two large Phase III cohorts designed to test the efficacy and
safety of INS37217 over a six-month efficacy interval and six-month open label safety interval
has been fully enrolled (365 subjects;Tiger1). Enrollment in the replicate Tiger2 study is
underway.
Moli-1901—(Lantibio/AOP Orphan Pharmaceuticals AG) is currently in Phase II clinical
trials in Europe. This 19 residue polycyclic peptide is known to increase free intracellular
Ca2+ concentrations [20] through release of calcium from endoplasmic reticulum stores. In
both normal and CF epithelia, Moli-1901 stimulates a Ca2+-dependent increase in short circuit
current that is consistent with activation of CaCC, the same conductance activated by P2Y
agonists. However, unlike P2Y agonists, there is no proposed mechanism to simultaneously
inhibit Na+ absorption. Phase I clinical trials have demonstrated that CF nasal potential
difference is sensitive to superfusion of Moli-1901. However, the effects were transient (< 2
min) at lower doses and the authors suggested that desensitization during repeated low doses
may be an issue [21]. A small but cumulative change in nasal PD was observed at higher doses,
with a maximal change (~15 mV) in nasal PD at 3 µM Moli-1901. The half life of the drug is
64 days in rat lung [22] and, therefore, even modest increases in chloride transport may be
clinically relevant if the effects are sustained. Lantibio reported that the drug is tolerated well
at daily inhaled doses of 2.5 mg, and that in a 28 day period there is an increase in FEV1 of
+2% vs. the −3% for placebo controls [21].
C. Na+ channel blockers
The airway epithelial Na+ channel (ENaC) is activated by a series of proteolytic steps that
occur within the cell, e.g., furin-mediated, and on the cell surface, channel-activating protease
(CAP) mediated [3,23]. Thus, there have been two strategies to block the excessive and
unregulated Na+ transport that characterizes CF airways.
First, there is a program to block what may be the predominant cell surface CAP expressed on
airway cells, i.e., prostasin (CAP1). In vitro data have indicated that a compound previously
studied in Japan for pancreatitis, QAU145 (Novartis), will inhibit short-circuit current mediated
by Na+ transport in excised guinea pig trachea and increase mucus transport in sheep over
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short- and long-term intervals [24]. Phase I studies of QAU145, in the nose for safety, and its
ability to inhibit ENaC-mediated Na+ transport, have been initiated.
A second approach is to block the Na+ channel from the airway surface utilizing an open
channel blocker. The classic Na+ channel blocker is amiloride [25]. Amiloride has been
extensively tested as pharmacotherapy for CF lung disease. The results have been mixed,
exhibiting short-term actions to improve mucociliary clearance and, as monotherapy,
protecting lung function. However, when amiloride is added to the usual mix of
pharmacotherapies for treating the CF patient in the modern era, no therapeutic benefits of
amiloride have been detected. A series of pharmacokinetic studies have suggested that part of
the reason amiloride may be ineffective is that it is very rapidly absorbed from the airway
surface, so full block may not be achieved.
Based on these considerations, a series of extremely potent (>100X amiloride) and longer-
acting Na+ channel blockers have been developed for aerosol delivery [26]. The first of these
third generation amiloride analogs, PS552, was thoroughly tested in a pre-clinical program.
PS552 was found to be more potent and selective than amiloride and without pathologic effects
in the lung. Because most small molecules inhaled into the lung are ultimately absorbed, a
dose-limiting parameter for Na+ channel blockers is exposure of the kidney to absorbed drug.
PS552 is designed, in contrast to amiloride, to be primarily hepatically excreted to avoid
naturetic and anti-kaluretic effects. Studies in sheep showed durable (>4 hr) effects on mucus
clearance from single inhalations of PS552 [27].
In Phase I studies, PS552 was shown to be safe and without detectable naturetic or anti-kaluretic
effects (2 mg, q.d., PariLCStar). Pharmacodynamic Phase IB studies revealed that, as in the
sheep, PS552 had a measureable pharmacodynamic enhancement of mucus clearance in normal
humans for > 4 hr. In a two-week Phase 2A study, no untoward effects were observed on renal
function, and post-hoc analyses revealed trends for protecting against loss of lung function in
treated versus vehicle-dosed subjects. Currently, a fourth-generation inhaled Na+ channel
blocker (GS680) is under development for CF pharmacotherapy as an aerosol by Parion/Gilead
Sciences.
D1. Novel therapeutic entities – Correctors
In the last decade, two novel classes of drugs have made progress as potential therapies for CF,
correctors and potentiators [28–30]**. Corrector drugs are designed to allow mutated CFTR
to bypass the endogenous quality control systems in the cell and reach the apical membrane.
Consequently, these drugs may correct the biogenesis problem in CF and promote trafficking
of mutated CFTR protein to the plasma membrane, where most mutated proteins, including
ΔF508, exhibit partial Cl− channel function [31] (Figure 3). If every CF cell could traffic even
modest amounts of ΔF508 CFTR to the apical membrane, there could be substantial therapeutic
gain [32]*. The corrector 4-phenylbutyrate (transcriptional regulator and chemical chaperone)
produces a marginal increase in mature CFTR in the apical membrane [29], whilst the effects
of curcumin (plant product with a variety of bioactive properties) are more debatable [33].
However, a recent study with an analog of sildenafil (phosphodiesterase 5 inhibitor, aka
Viagra), KM11060, reported that this drug (at 37°C) can traffic mutated CFTR to the apical
membrane with an efficiency of ~80% of that produced by reduced temperature [34]. Most of
these drugs are still in early development although 4-phenylbutyrate/genistein dual therapy is
in recruitment for phase 2 trials.
D2. Novel therapeutic entities – Potentiators
Potentiator drugs have also reached phase 1 and 2 clinical trials. This set of drugs targets
mutated CFTR present in the apical membrane and is designed to augment the ion channel
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function of these proteins. The CFTR mutations that are especially amenable to this approach
are the mutated channels that already reach the membrane but display less functional activity
than wild-type. Two such mutations are R117H and G551D. R117H is present in 0.8–2% of
the CF population (The Cystic Fibrosis Genetic Analysis Consortium) and results in mutated
but mature CFTR protein that demonstrates a lower open probability (PO ~0.1) than wild type
CFTR [PO ~0.35–0.40 [35,36]. G551D also reaches the plasma membrane as a mature protein.
However, it demonstrates severely diminished open probability, PO ~0.04 [37], and is present
in 2–6% of CF patients (The Cystic Fibrosis Genetic Analysis Consortium). The plant
isoflavone genistein, a phytoestrogen, has been well documented [37–39], at concentrations
of ~50 µM or greater, to activate mutated CFTR in the epithelium. It is, however, difficult to
achieve these concentrations, since genistein bioavailability by oral administration is very low
[40].
Consequently, there has been a search to find more potent and specific CFTR potentiators than
genistein. Two compounds are in development by Vertex Pharmaceuticals, in collaboration
with Cystic Fibrosis Foundation Therapeutics, and they are currently in phase 1 and phase 2
clinical trials. Oral VX-770 is in phase 2 trials in G551D genotype CF patients. VX-809 is
currently in phase 1A trials and expected to enter phase 1B trials in mid 2008. In vitro patch
clamp studies, carried out on CFTR expressed in Fisher Rat Thyroid cells, have demonstrated
that VX-770 increases ΔF508 PO from 0.11 ± 0.05 to 0.45 ± 0.06, and G551D PO from 0.08
± 0.03 to 0.52 ± 0.19 [41]**. These data suggest that VX-770 can increase ΔF508 and G551D
PO to values in the range reported for wild type CFTR. Chloride secretion across Fisher Rat
Thyroid monolayers over-expressing ΔF508 in Ussing chambers in response to VX770 was
somewhat less robust, with an increase above a very low basal short circuit current of ~2 fold
[41]. The data are not surprising, since the quantity of ΔF508 CFTR protein in the membrane
is presumably small. However, the increase in G551D current was 14-fold, representing 65%
of the current carried by wild type CFTR in this system. Importantly, VX-770 is more potent
than genistein, with an EC50 of ~600 nM, and is reported to be orally bioavailable [41]. Likely,
for ΔF508 CF patients, dual therapy will be required, with corrector to traffic mutated CFTR
protein to the apical membrane and potentiators such as VX-770 to stimulate activation.
4. CONCLUSIONS
This is an exciting period for pharmacotherapy of CF in general and CF lung disease in
particular. The hard-won scientific work that led to insights into the molecular and lung-specific
pathogenesis of CFTR mutations has borne fruit in the context of more specific and, hence,
likely effective pharmacotherapies. The correctors, in particular, offer the chance to treat CF
systemically and effectively. Because CF lung disease evolves episodically, the development
of hydrating agents offers the possibility of arresting the progression of CF lung disease and
indeed, in infants, preventing CF lung disease.
However, challenges remain. Because CF lung disease is now a truly chronic disease, the signs
that indicate signal efficacy are becoming increasingly difficult to detect in classic two-four
week Phase II trials. Thus, there is a great need for biomarkers that are sensitive to the severity
of lung disease and signaling efficacy of novel compounds over this time interval. In parallel,
the wealth of new drugs has made it difficult to recruit large numbers of subjects for definitive
Phase III trials. Further, the apparent activity of HS as an effective osmotic therapy has made
the decision to remove patients from this form of therapy to enroll in trials that require control
groups off HS therapy difficult for clinical investigators. However, in the broad scheme of CF
pharmacotherapy, as compared to the previous era, these are good problems to have.
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Pathogenesis of CF. Cystic fibrosis remains the most common potentially lethal genetic disease
of Caucasians in North America, Europe, and New Zealand and Australia. The median age for
survival of CF patients is presently 36 years, and a persistent bacterial bronchitis/bronchiectasis
is the most common cause of mortality. The increased life-span to 36 years reflects, in large
part, better antimicrobial therapy for pulmonary infections and better attention to nutrition and
treatment of pancreatic dysfunction. Cystic fibrosis lung disease results from a failure of innate
lung defense mechanisms as a result of airway dehydration. Normal airways (NL, left panel)
exhibit a periciliary layer (PCL) of ~7 µM, a height at which cilia can extend fully and beat
effectively to propel the overlying mucus blanket. A balance of CFTR-mediated Cl− secretion
and ENaC–mediated Na+ absorption keeps the periciliary layer sufficiently hydrated to support
this mucociliary clearance. (Middel Panel) In the absence of CFTR (as in CF), Cl− secretion
is severely diminished. In parallel, ENaC is poorly regulated in the absence of CFTR function
and the result is inappropriate rates of Na+ absorption. This dysregulated absorption causes the
PCL to become depleted of liquid and the mucus blanket to become concentrated, which
produces adhesion to collapsed cilia and arrest of mucociliary clearance. (Right panel) To
restore normal mucociliary clearance to CF airways, either or both ion transport defects must
be modified to match the normal airway functions, i.e., increase Cl− secretion and/or decrease
Na+ absorption. Addition of osmolytes to the apical domain (e.g. hypertonic saline, HS)
generates an osmotic driving force for liquid transport into the surface compartment because
the airway epithelium is very water permeable (low resistance epithelium and abundance of
aquaporins). Osmotic therapies directly deposit osmoles on airway surfaces, whereas ion
channel modulators add osmoles to the surface by producing net NaCl secretion. Both strategies
rehydrate the PCL and dilute mucins in the the mucus layer, which restores the effective beat
stroke of cilia and mucociliary clearance.
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Summary of the pharmacotherapeutic targets for the treatment of CF lung disease. Of all of
the drug therapies in development that are designed to restore airway hydration and promote
mucociliary clearance, the osmotic agents are by far the furthest ahead in the development
pipeline. Since the airway epithelium is highly water permeable, addition of osmotic agents to
the apical surface (1), either using hypertonic saline or mannitol, sets up an osmotic gradient
that drives fluid to the apical surface. Small but significant clinical gains in FEV1 have been
reported, but more importantly the frequency of exacerbations are significantly reduced while
on this therapy. Phase III clinical trials for hypertonic saline have been completed and this
therapy is now available in most CF clinics. In the early 1990s, it was found that apically applied
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P2Y2 receptor agonists (ATP/UTP) elicited a chloride secretory response in both normal and
cystic fibrosis airways. The presence of this alternative Ca2+ activated Cl− secretory pathway
has been recognized as a potential pharmacotherapeutic target (2). Two leading drugs that
target this pathway are the P2Y2 receptor analog Dunufosol (Inspire 37217) and (3) the Ca2+-
raising agent Moli-1901 (Lantibio). Denufosol, by activating P2Y2 receptors, increases the rate
of PIP2 hydrolysis, resulting in an increase in IP3 and release of Ca2+ from stores. Whilst the
increase in free intracellular Ca2+ activates Cl− secretion through calcium activated chloride
channels (CaCC), the drop in PIP2 levels, as a result of its hydrolysis, leads to a decrease in
ENaC activity. The agent Moli-1901, a polycyclic peptide, is known to interact with
phospholipids in the plasma and organellar membranes, and elevate intracellular Ca2+. This in
turn leads to activation of CaCC.
In addition, ENaC-mediated absorption is known to be dysregulated in CF due to the lack of
CFTR-mediated inhibition of ENaC. Therefore, this channel has been targeted to reduce the
abnormal absorption of Na+ in CF airways (4). The amiloride-analogs PS552/P680 (Parion
Sciences, Parion/Gilead, respectively) are open channel blockers, whilst QAU145 (Novartis)
inhibits the serine proteases (Channel Activating Proteins - CAP inhibitor) that activate ENaC
under normal physiological conditions. The strategy of blocking absorption should result in a
net secretory activity and improved airway hydration.
For ΔF508 patients, the absence of CFTR protein in the membrane reduces secretion and allows
absorption via ENaC to continue unregulated. Corrector drugs (5a) are designed to facilitate
trafficking of ΔF508-CFTR to the apical membrane, where it is known that they have residual
functional activity. If ΔF508-CFTR can be trafficked to the membrane, potentiator drugs (5b)
have been designed to increase mutated CFTR function. In addition, some mutations in CF,
namely G551D and R117H, represent mutated proteins that successfully traffick to the
membrane but have limited functionality. The potentiator drug VX-770 (Vertex) is currently
in clinical trials, and aims to improve the function of G551D mutated CFTR in the airway
epithelium. In vitro studies have already confirmed increased functionality of mutated protein
using this compound but the clinical gains have yet to be evaluated.
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CFTR mutations and correction/potentiation of their function. There are more than 1500
mutations in the CFTR gene, but more than 70% of CF chromosomes exhibit a single mutation,
i.e., a three base pair deletion that results in an absence of phenylalanine at position 508 of the
CFTR protein (ΔF508 CFTR). This mutation, and many others, produces a dysfunction in the
biogenesis of functional CFTR protein. Many signals promote the maturation of wild-type
CFTR protein, but they are not accessed by mutated CFTR and, hence, mutated proteins do
not fold appropriately. Misfolded proteins recognized as being “abnormal” by cells are
degraded intracellularly, in part by proteosomes. An important observation is that folding of
CFTR is temperature-sensitive, and low temperature allows a small fraction of mutant CFTR
to fold appropriately ([42]). If mutant CFTR protein reaches the apical cell membrane, the
normal cellular location for CFTR, in response to low temperature, it may exhibit partial Cl−
channel function but a short residency time on the cell surface. Cl− secretion via CFTR is the
main tonic pathway mediating normal hydration of airway surfaces. Thus CFTR represents a
potential major therapeutic target in the treatment of CF. CF lung disease can result from a
spectrum of mutations in the CFTR protein. Normally, wild type CFTR (Panel 1) is trafficked
to the apical membrane, where its function is regulated by a number of pathways, primarily by
PKC/PKA-activation. The channel displays spontaneous activity, but its open times increase
in frequency and duration upon activation. A wild-type CFTR Cl− channel likely has a mean
open probability (PO) of ~0.4 in situ. The most frequent and deleterious mutation of CFTR is
the deletion of phenylalanine at position 508 (ΔF508). This results in misfolding of the protein
and degradation of the protein before it matures and traffics to the plasma membrane (Panel
2), i.e., mutated protein is recognized and broken down within the cell. Thus ΔF508-CFTR is
very scarce/absent in the plasma membrane. Under low temperature conditions, a small fraction
of ΔF508-CFTR can traffic to the cell membrane in some cell types and displays residual
Cl− transport capabilities. However, its function is limited both by its low open probability
(PO <0.1) and the rapid turnover of ΔF508 CFTR in the apical membrane. G551D-CFTR (Panel
3) does mature/traffic properly and is found in the apical membrane, but its functional activity
is severely reduced by its very low open probability (PO <0.04). This defect results in an
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epithelium with a low Cl− secretory capacity. Another mutation that results in mature protein
at the apical membrane is R117H-CFTR (Panel 4). This protein exhibits flickery single channel
kinetics and a reduced open probability (PO <0.1) compared to wild type CFTR, but it does
exhibit sufficient Cl− secretory capacity to delay the onset of severe clinical signs of CF, e.g.,
the prognosis for ΔF508/R117H heterozygotes is significantly better than for ΔF508
homozygotes. To target mutated CFTR pharmacotherapeutically requires that mutated CFTR
be present in the membrane, e.g., as is the case for G551D and R117H. For ΔF508 mutations,
the mutated protein must be trafficked to the membrane first (drugs designed to do this are
termed correctors), and secondly, the function of the mutated channel must be improved (drugs
designed to increase channel function are termed potentiators).
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Table 1
Summary of the leading drug therapies for the correction of ion transport deficiency in cystic fibrosis.
Mechanism of Action Drug Company Clinical Trial Phase Ref
CFTR Vertex Corrector Vertex Pre-clinical [43]
correction – trafficks mutated protein to the membrane UCSF Corrector UCSF Research [44]
CFTR VX-770 Vertex Phase II [28,41]
potentiation – improves mutated CFTR function VX-809 Vertex Phase Ia
Alternative Cl− Denufosol Inspire Phase III [19]
secretion Moli-1901 Lantibio Phase II [21]
Na+ absorption P-552 Parion Phase II [26,27]
Inhibitor P-680 Parion/Gilead Pre-clinical
QAU145 Novartis Phase II [24]
Osmolytes Hypertonic NaCl Available [14,16]
Bronchitol Pharmaxis Phase III [12,17]
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